MCID: GLC051
MIFTS: 13

Glaucoma 1, Open Angle, M malady

Aliases & Classifications for Glaucoma 1, Open Angle, M

Aliases & Descriptions for Glaucoma 1, Open Angle, M:

Name: Glaucoma 1, Open Angle, M 54 29 13

Characteristics:

HPO:

32
glaucoma 1, open angle, m:
Inheritance autosomal dominant inheritance


External Ids:

OMIM 54 610535

Summaries for Glaucoma 1, Open Angle, M

MalaCards based summary : Glaucoma 1, Open Angle, M and has symptoms including primary open angle glaucoma and constriction of peripheral visual field. An important gene associated with Glaucoma 1, Open Angle, M is GLC1M (Glaucoma 1, Open Angle, M (Juvenile-Onset)). The drugs Brinzolamide and Timolol have been mentioned in the context of this disorder.

Description from OMIM: 610535

Related Diseases for Glaucoma 1, Open Angle, M

Diseases in the Glaucoma 1, Open Angle, H family:

Glaucoma 1, Open Angle, M Glaucoma 1, Open Angle, N

Symptoms & Phenotypes for Glaucoma 1, Open Angle, M

Symptoms by clinical synopsis from OMIM:

610535

Clinical features from OMIM:

610535

Human phenotypes related to Glaucoma 1, Open Angle, M:

32
id Description HPO Frequency HPO Source Accession
1 primary open angle glaucoma 32 HP:0012108
2 constriction of peripheral visual field 32 HP:0001133

Drugs & Therapeutics for Glaucoma 1, Open Angle, M

Drugs for Glaucoma 1, Open Angle, M (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Brinzolamide Approved Phase 4,Phase 3 138890-62-7 68844
2
Timolol Approved Phase 4,Phase 3,Phase 2 26839-75-8 33624 5478
3
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
4
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
5
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130209-82-4 5282380 5311221
6
Sorbitol Approved Phase 4 50-70-4 5780
7
Maleic acid Experimental Phase 4 110-16-7 444266
8 Adrenergic Agents Phase 4,Phase 3,Phase 2
9 Adrenergic Agonists Phase 4,Phase 2
10 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
11 Adrenergic alpha-Agonists Phase 4,Phase 2
12 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
13 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2
14 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
15 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Brimonidine Tartrate Phase 4,Phase 2 70359-46-5
17 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
19 Ophthalmic Solutions Phase 4,Phase 3,Phase 2
20 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
21 Cloprostenol Phase 4
22 Contraceptive Agents Phase 4
23 Luteolytic Agents Phase 4
24 Cathartics Phase 4
25 Gastrointestinal Agents Phase 4
26 Laxatives Phase 4
27 Anticoagulants Phase 4
28 Blood Substitutes Phase 4
29 Dextrans Phase 4
30 Lubricant Eye Drops Phase 4
31 Plasma Substitutes Phase 4
32 Tetrahydrozoline Phase 4,Phase 3
33 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
34 Alkylating Agents Phase 4
35 Anti-Bacterial Agents Phase 4
36 Antibiotics, Antitubercular Phase 4
37 Mitomycins Phase 4
38 Nucleic Acid Synthesis Inhibitors Phase 4
39
Ephedrine Approved Phase 3 299-42-3 9294
40
Pseudoephedrine Approved Phase 3 90-82-4 7028
41 Autonomic Agents Phase 3
42 Nasal Decongestants Phase 3
43 Peripheral Nervous System Agents Phase 3
44 Respiratory System Agents Phase 3
45 Vasoconstrictor Agents Phase 3
46
Dorzolamide Approved Phase 2 120279-96-1 3154 5284549
47 Antioxidants Phase 1, Phase 2
48
Epigallocatechin gallate Phase 1, Phase 2 989-51-5 65064
49 Neuroprotective Agents Phase 1, Phase 2
50 Protective Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 40)
id Name Status NCT ID Phase
1 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4
2 Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Completed NCT01937312 Phase 4
3 Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Completed NCT01937299 Phase 4
4 A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma Completed NCT00887029 Phase 4
5 Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Completed NCT02003391 Phase 4
6 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4
7 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4
8 Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Completed NCT00799682 Phase 4
9 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Recruiting NCT02792803 Phase 4
10 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil Terminated NCT01514734 Phase 4
11 A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy Terminated NCT00597181 Phase 4
12 Travacom Post Marketing Surveillance Study Withdrawn NCT01510132 Phase 4
13 Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations Completed NCT01306461 Phase 3
14 Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Recruiting NCT02801617 Phase 3
15 Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension Recruiting NCT02247804 Phase 3
16 Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension Recruiting NCT02250651 Phase 3
17 1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT Terminated NCT00767481 Phase 3
18 Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma Unknown status NCT00476138 Phase 1, Phase 2
19 Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT01528111 Phase 1, Phase 2
20 A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma Completed NCT02014142 Phase 2
21 Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma Completed NCT00317577 Phase 2
22 Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide Completed NCT01062971 Phase 2
23 Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure Completed NCT02057575 Phase 2
24 Comparison Between Deep Sclerectomy and Traditional Trabeculotomy & Trabeculectomy in Congenital Glaucoma Unknown status NCT01460017 Phase 1
25 Safety Study of Latanoprost Slow Release Insert Terminated NCT01180062 Phase 1
26 Near to Infrared (NIR) Light Neuroprotection in Glaucomatous Optic Neuropathy Unknown status NCT00844389 Early Phase 1
27 The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma Unknown status NCT01020721
28 Diagnostic Innovations in Glaucoma Study Unknown status NCT00221897
29 Optical Coherence Tomography Quantitative Analysis of Changes in Anterior Chamber After Laser Peripheral Lridotomy Unknown status NCT02279472
30 Spectral Domain Optical Coherence Tomography Analysis for Glaucoma Completed NCT01612416
31 Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma? Completed NCT00312403
32 Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma Completed NCT01058278
33 Effect of Yellow-Tinted Intraocular Lens on Standard Automated Perimetry (SAP) and Short-wavelength Automated Perimetry (SWAP) in Patients With and Without Glaucoma Completed NCT01305616
34 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed NCT00121147
35 Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects Completed NCT00712400
36 Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure Completed NCT01923454
37 Evaluation of the Possibility to Delegate Glaucoma Surveillance to Orthoptists in Hospital Recruiting NCT02876185
38 Corneal Endothelial Cell Loss After Trabeculectomy Versus Phakotrabeculectomy Not yet recruiting NCT03107000
39 Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery Terminated NCT00644280
40 Prevalence of Dyschromatopsia in Glaucoma Patients Withdrawn NCT01994564

Search NIH Clinical Center for Glaucoma 1, Open Angle, M

Genetic Tests for Glaucoma 1, Open Angle, M

Genetic tests related to Glaucoma 1, Open Angle, M:

id Genetic test Affiliating Genes
1 Glaucoma 1, Open Angle, M 29

Anatomical Context for Glaucoma 1, Open Angle, M

Publications for Glaucoma 1, Open Angle, M

Variations for Glaucoma 1, Open Angle, M

Expression for Glaucoma 1, Open Angle, M

Search GEO for disease gene expression data for Glaucoma 1, Open Angle, M.

Pathways for Glaucoma 1, Open Angle, M

GO Terms for Glaucoma 1, Open Angle, M

Sources for Glaucoma 1, Open Angle, M

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....